During the early stage of MPN, clonal cells are usually responsive to hydroxyurea (HU), interferon-alpha (IFN-A), and/or Ruxolitinib, but this is not the case in most patients with advanced MPN or sAML. The gene discussed is IFNA1; the disease is myeloproliferative neoplasm.